Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene

Clinical Cancer Research

Volumn 14, Issue 8, 2008, Pages 2450-2457

  Luo, Jingjing ^a   Xia, Qingmei ^a   Zhang, Rui ^a   Lv, Chen ^a   Zhang, Wei ^a   Wang, Yingxin ^a   Cui, Qiang ^a   Liu, Li ^a   Cai, Rong ^a   Qian, Cheng ^a  

^a ZHEJIANG SCI TECH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 24; VIRUS VECTOR;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; INFECTION; PRIORITY JOURNAL; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; INTERLEUKINS; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; ONCOLYTIC VIROTHERAPY;

EID: 42249107656     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4596     Document Type: Article

References (38)

1. Qian C, Sangro B, Prieto J. New strategies to enhance gene therapy efficiency. Gastroenterology 2002;123:639-42.
2. McCormick F. Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer 2001;1:130-41.
3. Sangro B, Mazzolini G, Ruiz J, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004;22:1389-97.
4. Curiel DT. The development of conditionally replicative adenoviruses for cancer therapy. Clin Cancer Res 2000;6:3395-9.
5. Qian C, Liu XY, Prieto J. Therapy of cancer by cytokines mediated by gene therapy approach. Cell Res 2006;16:182-8.
6. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001;7:781-7.
7. Small EJ, Carducci MA, Burke JM, et al. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 2006;14:107-17.
8. Galanis E, Okuno SH, Nascimento AG, et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther 2005;12:437-45.
9. Hecht JR, Bedford R, Abbruzzese JL, et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003;9:555-61.
10. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879-85.
11. Hermiston TW, Kuhn I. Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Ther 2002;9:1022-35.
12. Bristol JA, Zhu M, Ji H, et al. In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Mol Ther 2003;7:755-64.
13. Bernt KM, Steinwaerder DS, Ni S, Li ZY, Roffler SR, Lieber A. Enzyme-activated prodrug therapy enhances tumor-specific replication of adenovirus vectors. Cancer Res 2002;62:6089-98.
14. Zhao L, Gu J, Dong A, et al. Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther 2005;16:845-58.
15. Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res 2001;61:8743-50.
16. Pei Z, Chu L, Zou W, et al. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Hepatology 2004;39:1371-81.
17. Liu XY, Qiu SB, Zou WG, et al. Effective gene-virotherapy for complete eradication of tumor-mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5. Mol Ther 2005;11:531-41.
18. Qiao J, Doubrovin M, Sauter BV, et al. Tumor-specific transcriptional targeting of suicide gene therapy. Gene Ther 2002;9:168-75.
19. Li X, Liu YH, Zhang YP, et al. Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy. Clin Cancer Res 2007;13:5463-73.
20. Mi J, Li ZY, Ni S, Steinwaerder D, Lieber A. Induced apoptosis supports spread of adenovirus vectors in tumors. Hum Gene Ther 2001;12:1343-52.
21. Akbulut H, Zhang L, Tang Y, Deisseroth A. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon. Cancer Gene Ther 2003;10:388-95.
22. Yoder SS, Robberson BL, Leys EJ, et al. Control of cellular gene expression during adenovirus infection: induction and shut-off of dihydrofolate reductase gene expression by adenovirus type 2. Mol Cell Biol 1983;3:819-28.
23. Zhang Y, Schneider RJ. Adenovirus inhibition of cell translation facilitates release of virus particles and enhances degradation ofthe cytokeratin network. J Virol 1994;68:2544-55.
24. Rivera AA, Wang M, Suzuki K, et al. Mode of transgene expression after fusion to early or late viral genes of a conditionally replicating adenovirus via an optimized internal ribosome entry site in vitro and in vivo. Virology 2004;320:121-34.
25. Carette JE, Graat HC, Schagen FH, Abou El Hassan MA, Gerritsen WR, van Beusechem VW. Replication-dependent transgene expression from a conditionally replicating adenovirus via alternative splicing to a heterologous splice-acceptor site. J Gene Med 2005;7:1053-62.
26. Hawkins LK, Johnson L, Bauzon M, et al. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region. Gene Ther 2001;8:1123-31.
27. Jin F, Kretschmer PJ, Hermiston TW. Identification of novel insertion sites in the Ad5 genome that utilize the Ad splicing machinery for therapeutic gene expression. Mol Ther 2005;12:1052-63.
28. Bauzon M, Castro D, Karr M, Hawkins LK, Hermiston TW. Multigene expression from a replicating adenovirus using native viral promoters. Mol Ther 2003;7:526-34.
29. Young CS. The structure and function of the adenovirus major late promoter. Curr Top Microbiol Immunol 2003;272:213-49.
30. Wold WS, Tollefson AE, Hermiston TW. E3 transcription unit of adenovirus. Curr Top Microbiol Immunol 1995;199:237-74.
31. Fisher PB, Gopalkrishnan RV, Chada S, et al. mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol Ther 2003;2:S23-37.
32. Lebedeva IV, Sauane M, Gopalkrishnan RV, et al. mda-7/IL-24: exploiting cancer's Achilles' heel. Mol Ther 2005;11:4-18.
33. Caudell EG, Mumm JB, Poindexter N, et al. The protein product oft he tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol 2002;168:6041-6.
34. Nishikawa T, Munshi A, Story MD, et al. Adenoviral-mediated mda-7 expression suppresses DNA repair capacity and radiosensitizes non-small-cell lung cancer cells. Oncogene 2004;23:7125-31.
35. Zhang W, Cai R, Luo JJ, et al. The oncolytic adenovirus targeting to TERT and RB pathway induced specific and potent anti-tumor efficacy in vitro and in vivo for hepatocellular carcinoma. Cancer Biol Ther 2007;6:1726-32.
36. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.
37. Cunningham CC, Chada S, Merritt JA, et al. Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol Ther 2005;11:149-59.
38. Tong AW, Nemunaitis J, Su D, et al. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther 2005;11:160-72.